Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment ...
Most-Favored-Nation rhetoric and international reference proposals can become practical anchors despite unclear ...
Cencora's Gregg Gorniak breaks down what separates basic DSCSA compliance from using it to streamline transactions and ...
Cardinal Health's Liberty Dewey breaks down the NDC-12 transition timeline and the vendor, association and wholesaler support ...
Increasing disruption and higher-value, time-critical therapies are eroding the historical “package-and-pray” model, because packaging can only protect within defined limits as variability becomes ...
HDA's Kala Shankle explains what a national licensure standard could mean for wholesale distributors and 3PLs, and why its ...
Ahead of HDA's 2026 Traceability Seminar, Cencora's Gregg Gorniak explains how AI and RFID are being used to catch DSCSA data ...
McKesson's Scott Mooney discusses the technical and operational challenges of DSCSA compliance, from linking ERP systems to EPCIS to recurring friction in 340B transaction data exchange. Serialized ...
In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings. Welcome to ...
Of the seven principles set out in the Council for International Organizations of Medical Sciences Working Group (CIOMS) ...
Cencora's Ameer Ali explains how the shift to NDC-12 is reshaping supply chain systems and why readiness still varies widely across manufacturers. As the FDA's shift to 12-digit National Drug Codes ...
Small‑molecule generics compete on bioequivalence via 505(j) ANDA, operational scale, and first‑to‑file dynamics, with predictable timelines followed by steep multi‑entrant price compression.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results